Goldman Sachs Downgrades Jazz Pharmaceuticals (JAZZ) to Sell

Goldman Sachs analyst Graig Suvannavejh downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Sell with a price target of $128.00.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $136.80 yesterday.

You May Also Be Interested In

• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Raymond James Downgrades Accelerant Holdings (ARX) to Underperform
• UBS says this pharma name offers a robust case for stock outperformance